Tech Company Financing Transactions
Renasant Bio Funding Round
5AM Ventures, Atlas Venture and OrbiMed participated in a $54.5 million Seed capital raise for Renasant Bio. This venture round was announced on 7/10/2025.
Transaction Overview
Company Name
Announced On
7/10/2025
Transaction Type
Venture Equity
Amount
$54,500,000
Round
Seed
Investors
Proceeds Purpose
The company intends to use the funds to support further progression of its lead corrector program and ongoing discovery efforts for its potentiator program.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2630 Bancroft Way
Berkeley, CA 94704
USA
Berkeley, CA 94704
USA
Phone
Undisclosed
Website
Email Address
Overview
At Renasant Bio, we are pioneering a new approach to treating autosomal dominant polycystic kidney disease (ADPKD), a devastating genetic disorder with no disease-modifying therapies and the leading genetic cause of end-stage renal failure. Our mission is to develop small molecule correctors and potentiators that target the root cause of the disease, restoring the function of polycystin 1 and 2 (PC1/2) to halt disease progression.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Emily Conley
Browse more venture capital transactions:
Prev: 7/10/2025: Water Harvesting venture capital transaction
Next: 7/10/2025: Headway venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We report on every notable VC transaction. VC investment data records reported here are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs